139 related articles for article (PubMed ID: 33027714)
1. FATP2-targeted therapies - A role beyond fatty liver disease.
Qiu P; Wang H; Zhang M; Zhang M; Peng R; Zhao Q; Liu J
Pharmacol Res; 2020 Nov; 161():105228. PubMed ID: 33027714
[TBL] [Abstract][Full Text] [Related]
2. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase.
Falcon A; Doege H; Fluitt A; Tsang B; Watson N; Kay MA; Stahl A
Am J Physiol Endocrinol Metab; 2010 Sep; 299(3):E384-93. PubMed ID: 20530735
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of human fatty acid transport protein 2/very long chain acyl-CoA synthetase 1 (FATP2/Acsvl1) reveals distinct patterns of trafficking of exogenous fatty acids.
Melton EM; Cerny RL; DiRusso CC; Black PN
Biochem Biophys Res Commun; 2013 Nov; 440(4):743-8. PubMed ID: 24113382
[TBL] [Abstract][Full Text] [Related]
4. Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease.
Ran LS; Wu YZ; Gan YW; Wang HL; Wu LJ; Zheng CM; Ming Y; Xiong R; Li YL; Lei SH; Wang X; Lao XQ; Zhang HM; Wang L; Chen C; Zhao CY
J Nat Med; 2023 Jan; 77(1):73-86. PubMed ID: 36115008
[TBL] [Abstract][Full Text] [Related]
5. Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPARα-regulated genes.
Perez VM; Gabell J; Behrens M; Wase N; DiRusso CC; Black PN
J Biol Chem; 2020 Apr; 295(17):5737-5750. PubMed ID: 32188695
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
[TBL] [Abstract][Full Text] [Related]
7. Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2.
Alicea GM; Rebecca VW; Goldman AR; Fane ME; Douglass SM; Behera R; Webster MR; Kugel CH; Ecker BL; Caino MC; Kossenkov AV; Tang HY; Frederick DT; Flaherty KT; Xu X; Liu Q; Gabrilovich DI; Herlyn M; Blair IA; Schug ZT; Speicher DW; Weeraratna AT
Cancer Discov; 2020 Sep; 10(9):1282-1295. PubMed ID: 32499221
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells.
Krammer J; Digel M; Ehehalt F; Stremmel W; Füllekrug J; Ehehalt R
Int J Med Sci; 2011; 8(7):599-614. PubMed ID: 22022213
[TBL] [Abstract][Full Text] [Related]
9. FATP2 regulates non-small cell lung cancer by mediating lipid metabolism through ACSL1.
Chen Y; Zhao Y; Deng Y; Yang Y; Xu L; Fu J
Tissue Cell; 2023 Jun; 82():102105. PubMed ID: 37172427
[TBL] [Abstract][Full Text] [Related]
10. Water Extract of
Mun J; Kim S; Yoon HG; You Y; Kim OK; Choi KC; Lee YH; Lee J; Park J; Jun W
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31640183
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid transport protein-2 inhibitor Grassofermata/CB5 protects cells against lipid accumulation and toxicity.
Saini N; Black PN; Montefusco D; DiRusso CC
Biochem Biophys Res Commun; 2015 Sep; 465(3):534-41. PubMed ID: 26284975
[TBL] [Abstract][Full Text] [Related]
12. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway.
Fan Y; He Z; Wang W; Li J; Hu A; Li L; Yan L; Li Z; Yin Q
Biomed Pharmacother; 2018 Oct; 106():733-737. PubMed ID: 29990865
[TBL] [Abstract][Full Text] [Related]
13. Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.
Tharp KM; Khalifeh-Soltani A; Park HM; Yurek DA; Falcon A; Wong L; Feng R; Atabai K; Stahl A
Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(10):G855-64. PubMed ID: 27033116
[TBL] [Abstract][Full Text] [Related]
14. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
15. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
16. Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis.
Chen Y; Yan Q; Lv M; Song K; Dai Y; Huang Y; Zhang L; Zhang C; Gao H
Cell Death Dis; 2020 Nov; 11(11):994. PubMed ID: 33219209
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
18. Kidney Proximal Tubule Lipoapoptosis Is Regulated by Fatty Acid Transporter-2 (FATP2).
Khan S; Cabral PD; Schilling WP; Schmidt ZW; Uddin AN; Gingras A; Madhavan SM; Garvin JL; Schelling JR
J Am Soc Nephrol; 2018 Jan; 29(1):81-91. PubMed ID: 28993506
[TBL] [Abstract][Full Text] [Related]
19. meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells.
Lee MS; Kim KJ; Kim D; Lee KE; Hwang JK
Biol Pharm Bull; 2011; 34(10):1628-30. PubMed ID: 21963507
[TBL] [Abstract][Full Text] [Related]
20. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice.
Yang H; Yang T; Heng C; Zhou Y; Jiang Z; Qian X; Du L; Mao S; Yin X; Lu Q
Phytother Res; 2019 Dec; 33(12):3140-3152. PubMed ID: 31452288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
